A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission

Condition studied

Heart failure in remission

Investigational medicinal product(s)

Eligibility

Primary endpoint

Left ventricular remodeling, measured in a core echocardiography laboratory as an increase in left ventricular end-systolic volume index of more than 20% from baseline, NT-proBNP increase to more than 500 pg/mL, All-cause mortality

Endpoint detail

Time to first occurrence of all-cause mortality or all-cause hospitalizations, Change in KCCQ-12, Proportion of patients requiring HF treatment re-initiation or escalation (i.e., (re-)initation of at least one guideline-directed medical therapy or starting a loop diuretic)